valsartan has been researched along with aldosterone in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.17) | 18.2507 |
| 2000's | 30 (51.72) | 29.6817 |
| 2010's | 20 (34.48) | 24.3611 |
| 2020's | 5 (8.62) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, N; Inukai, T; Kometani, M; Nakao, K; Yamamoto, S | 1 |
| Clair, MJ; de Gasparo, M; Hebbar, L; Iannini, JP; Krombach, RS; Melton, DM; Mukherjee, R; O, SJ; Spinale, FG; Whitebread, S | 1 |
| Chiang, YT; Gatlin, M; Glazer, R; Pool, JL | 1 |
| Agarwal, R; Bakris, GL; Bolton, WK; Catanzaro, D; Hebert, L; Janssen, I; Richardson, D; Siomos, M | 1 |
| Bieringer, M; Breu, V; Dechend, R; Fiebeler, A; Haller, H; Luft, FC; Müller, DN; Park, JK; Schmidt, F; Shagdarsuren, E | 1 |
| Florin, M; Liu, KL; Lo, M; Sassard, J | 1 |
| Miller, AB; Srivastava, P | 1 |
| Bruneval, P; Clozel, JP; de Gasparo, M; Hess, P; Nuesslein-Hildesheim, B | 1 |
| Andersson, OK; Elmfeldt, D; Friberg, PR; Fridman, KU; Wysocki, M | 1 |
| Calvillo, L; De Angelis, N; Fiordaliso, F; Funicello, M; Gobbi, M; Latini, R; Masson, S; Mennini, T | 1 |
| Düsing, R; Gohlke, P; Lottermoser, K; Unger, T; Vetter, H | 1 |
| Anand, IS; Chiang, YT; Cohn, JN; Glazer, R; Latini, R; Masson, S | 1 |
| Düsing, R; Lottermoser, K; Ulrich-Merzenich, G; Vetter, H | 1 |
| Bedigian, MP; Lu, L; Robinson, AD; Sun, Y; Weber, KT; Zhang, J | 1 |
| Hukai, D; Ishii, C; Kanamori, T; Ohbayashi, Y; Ohnishi, M; Ohno, K; Okabayashi, T; Ozawa, T; Sakaguchi, T; Sichiri, G; Tanaka, T; Tsutamoto, T; Tsutsui, T; Wada, A; Yokohama, H | 1 |
| Anzai, T; Hashimoto, K; Himeno, H; Imai, K; Kawana, M; Kitakaze, M; Koretsune, Y; Maruyama, S; Masaoka, Y; Matsubara, H; Matsuoka, T; Miyao, Y; Miyatake, K; Miyauchi, T; Nakamura, Y; Nomura, F; Okamoto, H; Ozono, K; Sekiya, M; Shinohara, H; Shintani, U; Shiraki, T; Takaoka, H; Tsutamoto, T; Yasumura, Y; Yokoya, K; Yokoyama, H | 1 |
| Crijns, HJ; Folkeringa, RJ; Pinto, YM | 1 |
| Huang, CX; Jiang, H; Jiang, XJ; Liang, YH; Wang, JM; Zhou, Y | 1 |
| Azizi, M; Bissery, A; Bura-Rivière, A; Camisasca, RP; Guyenne, TT; Ménard, J; Vaidyanathan, S | 1 |
| He, Y; Savoia, C; Touyz, RM; Yao, G | 1 |
| Siragy, HM; Xue, C | 1 |
| Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Nasonova, SN; Skvortsov, AA; Sychev, AV | 1 |
| Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T | 1 |
| Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Nasonova, SN; Orlova, IaA; Skvortsov, AA; Sychev, AV | 1 |
| Akdag, I; Filiz, G; Gullulu, M; Kahvecioglu, S; Savci, V | 1 |
| Andronescu, D; Bengus, A; Dragomir, P; Fierbinteanu-Braticevici, C; Negreanu, L; Tribus, L; Usvat, R | 1 |
| Jones, MR; Laragh, JH; Sealey, JE | 1 |
| Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K | 1 |
| Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T | 1 |
| Kushibiki, M; Okumura, K; Osanai, T; Tomita, H; Yamada, M | 1 |
| Akizuki, O; Inayoshi, A; Kitayama, T; Kusaka, H; Matsubara, M; Sasaki, K; Shirakura, S; Yao, K | 1 |
| Elenkova, A; Kirilov, G; Lozanov, V; Mitev, V; Orbetzova, M; Shigarminova, R; Zacharieva, S | 1 |
| Harbig, J; Jaworski, K; Miller, AG; Tan, G; Wilkinson-Berka, JL | 1 |
| Adachi, M; Aritomi, S; Hayata, M; Kakizoe, Y; Kitamura, K; Ko, T; Konda, T; Miyoshi, T; Shiraishi, N; Tomita, K; Uchimura, K; Wakida, N | 1 |
| Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Sakata, A; Tsukuda, K | 1 |
| Derbentseva, EA; Dralova, OV; Ermolaeva, AS; Maksimov, ML; Starodubtsev, AK | 1 |
| Ferrario, CM; Habibi, J; Hayden, MR; Locher, B; Nistala, R; Pulakat, L; Sinak, C; Sowers, JR; Whaley-Connell, A | 1 |
| Ebina, T; Hibi, K; Kimura, K; Kosuge, M; Kusama, I; Morita, S; Nozawa, N; Okuda, J; Ozaki, H; Tsukahara, K; Umemura, S; Yano, H | 1 |
| Bugaj, V; Kohan, DE; Mironova, E; Ramkumar, N; Rees, S; Roos, KP; Stockand, JD | 1 |
| Ardhanari, S; DeMarco, VG; Ferrario, CM; Habibi, J; Hayden, MR; Krueger, C; Pulakat, L; Rehmer, N; Sowers, JR; Whaley-Connell, A | 1 |
| Bode, C; Braunwald, E; Brunel, PC; Hoffman, EB; Morrow, DA; Prescott, MF; Ren, F; Rifai, N; Scirica, BM; Swedberg, K; Udell, JA | 1 |
| Born, J; Derad, I; Lehnert, H; Marshall, L; Nitschke, M; Sayk, F | 1 |
| Bathgate-Siryk, A; Dabul, S; Garcia, D; Koch, WJ; Lymperopoulos, A; McDonald, P; Rengo, G; Sturchler, E; Walklett, K | 1 |
| Bathgate-Siryk, A; Dabul, S; Jafferjee, M; Koch, WJ; Lymperopoulos, A; McDonald, P; Sturchler, E; Valero, TR | 1 |
| Bakris, G; Bharucha, DB; Chen, C; Ferguson, WG; Giles, TD; Li, H; Mallick, M; Oparil, S; Weber, MA | 1 |
| Albrecht, D; Averkov, O; Ayalasomayajula, S; Chandra, P; Jordaan, P; Kobalava, Z; Kotovskaya, Y; Langenickel, TH; Moiseev, V; Pal, P; Pavlikova, E; Prescott, MF; Rajman, I | 1 |
| Fujii, M; Ichikawa, M; Imagawa, M; Ishizuka, T; Kaeriyama, S; Konoshita, T; Makino, Y; Nakamura, H; Nakaya, T; Sato, S; Suzuki, J; Urabe, M; Wakahara, S; Yamada, M; Yamamoto, K; Zenimaru, Y | 1 |
| Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z | 1 |
| Kitzman, DW; Packer, M | 1 |
| Bislev, LS; Bjerregaard Pedersen, E; Langagergaard Rødbro, L; Nørgaard Bech, J; Rejnmark, L; Rolighed, L; Sikjaer, T | 1 |
| Duran, SH; Jung, S; Newhard, DK; Winter, RL | 1 |
| Danhof, M; Giraudel, J; Mochel, JP; Peyrou, M; Rigel, DF; Teng, CH | 1 |
| Emdin, M; Passino, C; Vergaro, G | 1 |
| Alba, PR; Bress, AP; Choi, ME; Cook, J; Dodson, JA; Fang, JC; He, T; Herrick, JS; King, JB; Levitan, EB; Mohanty, AF; Obi, EN; Patterson, OV; Russo, PA; Vardeny, O | 1 |
| Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Batiha, GE | 1 |
| Crespo-Leiro, MG; Escobar, C; Esteban-Fernández, A; Farré, N; Garcia, A; Luis-Bonilla, J; Nuñez, J | 1 |
| Babes, EE; Behl, T; Bungau, SG; Horvath, T; Iovanovici, DC; Moisi, M; Rus, M; Tit, DM; Vesa, CM | 1 |
| Handa, T; Ikushima, A; Inoue, Y; Ishii, A; Ishimura, T; Kato, Y; Minamino, N; Mori, KP; Mukoyama, M; Nishio, H; Ohno, S; Sugioka, S; Yamada, H; Yanagita, M; Yokoi, H | 1 |
3 review(s) available for valsartan and aldosterone
| Article | Year |
|---|---|
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Heart Failure; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2001 |
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Glucosides; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Obesity; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Prospective Studies; Quality of Life; Renin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
20 trial(s) available for valsartan and aldosterone
| Article | Year |
|---|---|
Dose-response efficacy of valsartan, a new angiotensin II receptor blocker.
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Posture; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cross-Over Studies; Female; Glomerular Filtration Rate; Humans; Kidney; Lisinopril; Male; Middle Aged; Potassium; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 2000 |
Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension; Infusions, Intravenous; Losartan; Male; Middle Aged; Receptor, Angiotensin, Type 1; Renal Circulation; Renin; Tetrazoles; Valine; Valsartan | 2002 |
Differential effect of acute angiotensin II type 1 receptor blockade on the vascular and adrenal response to exogenous angiotensin II in humans.
Topics: Adrenal Glands; Adult; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Endothelins; Heart Rate; Humans; Hydrocortisone; Injections, Intravenous; Interleukin-6; Male; Renin; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan; Vasoconstrictor Agents | 2003 |
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Cardiac Output, Low; Chronic Disease; Double-Blind Method; Follow-Up Studies; Humans; Tetrazoles; Valine; Valsartan | 2003 |
[Effects of angiotensin II on inflammation mediators in healthy subjects].
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cytokines; Humans; Inflammation Mediators; Interleukin-6; Male; Renin-Angiotensin System; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan; Vascular Cell Adhesion Molecule-1 | 2003 |
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Coronary Disease; Delayed-Action Preparations; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Drug Synergism; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Failure; Heart Function Tests; Humans; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Receptors, Angiotensin; Renin; Tetrazoles; Valine; Valsartan | 2004 |
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Topics: Administration, Oral; Adolescent; Adult; Aldosterone; Amides; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Drug Synergism; Feedback, Physiological; Fumarates; Humans; Male; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2004 |
[Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect o
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Renin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2005 |
[Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADK
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiac Output, Low; Chronic Disease; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling | 2006 |
The effect of valsartan, an angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in liver cirrhosis.
Topics: Adult; Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Creatinine; Female; Hemodynamics; Humans; Hypertension, Portal; Kidney; Liver Cirrhosis; Male; Metanephrine; Middle Aged; Natriuresis; Portal System; Renin; Romania; Single-Blind Method; Sodium; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2006 |
Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Blood Pressure; Circadian Rhythm; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Imidazoles; Irbesartan; Male; Middle Aged; Olmesartan Medoxomil; Prognosis; Radioimmunoassay; Reference Values; Renin; Renin-Angiotensin System; Single-Blind Method; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2007 |
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Captopril; Chi-Square Distribution; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hypertrophy, Left Ventricular; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Prospective Studies; Renin-Angiotensin System; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Valine; Valsartan | 2012 |
Intranasal angiotensin II in humans reduces blood pressure when angiotensin II type 1 receptors are blocked.
Topics: Administration, Intranasal; Adult; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Humans; Hydrocortisone; Male; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension.
Topics: Aldosterone; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Male; Maximum Tolerated Dose; Nebivolol; Patient Selection; Renin; Renin-Angiotensin System; Risk Assessment; Severity of Illness Index; Treatment Outcome; Valsartan | 2015 |
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Area Under Curve; Biomarkers; Biphenyl Compounds; Chronic Disease; Drug Administration Schedule; Drug Combinations; Endothelin-1; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Russia; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2016 |
Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Blood Pressure; Cholecalciferol; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Parathyroid Hormone; Postmenopause; Valsartan; Vitamin D Deficiency | 2018 |
A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen; Cardiomegaly; Creatinine; Dog Diseases; Dogs; Double-Blind Method; Drug Combinations; Electrolytes; Female; Male; Mitral Valve Insufficiency; Pilot Projects; Random Allocation; Tetrazoles; Valsartan | 2018 |
35 other study(ies) available for valsartan and aldosterone
| Article | Year |
|---|---|
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Dogs; Enalapril; Heart Rate; Hypertension; Hypertension, Renal; Male; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Tetrazoles; Valine; Valsartan | 1997 |
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardiac Output; Cardiac Pacing, Artificial; Diastole; Disease Models, Animal; Endothelins; Epinephrine; Heart Failure; Heart Rate; Hemodynamics; Norepinephrine; Pulmonary Artery; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1997 |
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Body Weight; Cardiovascular Diseases; Fibroblast Growth Factor 2; Heart; Immunohistochemistry; Mineralocorticoid Receptor Antagonists; NF-kappa B; Organ Size; Platelet-Derived Growth Factor; Rats; Receptors, Mineralocorticoid; Renin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Transcription Factor AP-1; Transforming Growth Factor beta; Valine; Valsartan | 2001 |
Salt sensitivity in genetically hypertensive rats of the Lyon strain.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Drug Resistance; Hypertension; Kidney; Male; Perindopril; Rats; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2001 |
Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Drug Combinations; Enalapril; Endothelium, Vascular; Hypertension; Male; Rats; Rats, Inbred SHR; Survival Analysis; Tetrazoles; Valine; Valsartan | 2000 |
Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Apoptosis; Cell Nucleus; Cells, Cultured; Down-Regulation; Heart Ventricles; Male; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen Type I; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Heart; In Situ Hybridization; Infusions, Parenteral; Male; Myocardium; Nephrectomy; NF-kappa B; Rats; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2004 |
Aldosterone levels after angiotensin receptor blocker treatment.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Disease Progression; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2004 |
Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Central Venous Pressure; Chromatography, High Pressure Liquid; Collagen; Heart; Hydroxyproline; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Organ Size; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2004 |
Transient receptor potential melastatin 7 ion channels regulate magnesium homeostasis in vascular smooth muscle cells: role of angiotensin II.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Division; Cells, Cultured; DNA Replication; Gene Expression Regulation; Homeostasis; Humans; Ion Channels; Ion Transport; Magnesium; Membrane Proteins; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Protein Biosynthesis; Protein Kinases; Protein Serine-Threonine Kinases; Rats; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Tetrazoles; Transfection; TRPM Cation Channels; Valine; Valsartan | 2005 |
Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor.
Topics: Adrenalectomy; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Cytochrome P-450 CYP11B2; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Insulin; Kidney; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; RNA, Messenger; Sodium Chloride; Steroid Hydroxylases; Tetrazoles; Tissue Distribution; Valine; Valsartan | 2005 |
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Cholesterol, Dietary; Diet, Atherogenic; Enzyme Activation; Eplerenone; Inflammation; Male; Mice; Muscle, Smooth, Vascular; NADPH Oxidases; Oxidative Stress; Spironolactone; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Proliferation; Disease Models, Animal; Diuretics; Fibrosis; Glomerulonephritis, Membranoproliferative; Ki-67 Antigen; Kidney; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Spironolactone; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Thoracic; beta-Galactosidase; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Male; Muscle, Smooth, Vascular; Oxidative Stress; Proto-Oncogene Proteins p21(ras); Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Renin-Angiotensin System; RNA, Small Interfering; Spironolactone; Tetrazoles; Tumor Suppressor Protein p53; Valine; Valsartan | 2007 |
Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Dimerization; Eplerenone; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Receptor, Angiotensin, Type 1; Spironolactone; Tetrazoles; Transglutaminases; Valine; Valsartan; Vasoconstriction; Vasodilation | 2008 |
Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
Topics: Adrenal Cortex; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cell Line; Cytochrome P-450 CYP11B2; Dihydropyridines; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Humans; Membrane Potentials; Patch-Clamp Techniques; Potassium Chloride; RNA, Messenger; Steroid 11-beta-Hydroxylase; Tetrazoles; Valine; Valsartan | 2008 |
Homocysteine, renin and aldosterone in patients with Cushing's syndrome.
Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Chromatography, High Pressure Liquid; Cushing Syndrome; Female; Fluorescence Polarization Immunoassay; Homocysteine; Humans; Male; Metabolic Syndrome; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2008 |
Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology.
Topics: Aldosterone; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Cattle; Cells, Cultured; Cytokines; Endothelial Cells; Eye Proteins; Glucosephosphate Dehydrogenase; Leukostasis; Mineralocorticoid Receptor Antagonists; NADPH Oxidase 4; NADPH Oxidases; Neovascularization, Pathologic; Oxidative Stress; Oxygen; Pericytes; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Renin-Angiotensin System; Retinal Vasculitis; Sodium Chloride; Spironolactone; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2009 |
Regulation of adrenal aldosterone production by serine protease prostasin.
Topics: Adrenal Cortex; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Channel Blockers; Cell Line; Cytochrome P-450 CYP11B2; Dihydropyridines; Gene Expression Regulation; Gene Silencing; Humans; Nitrophenols; Organophosphorus Compounds; Promoter Regions, Genetic; Rats; Receptors, Proteinase-Activated; Recombinant Proteins; Serine Endopeptidases; Tetrazoles; Transfection; Valine; Valsartan | 2010 |
Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism.
Topics: Aldosterone; Angiotensin II; Animals; Astrocytes; Cells, Cultured; DNA Damage; Eplerenone; Ganglia, Spinal; Mice; Mice, Inbred C57BL; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone; Tetrazoles; Valine; Valsartan | 2011 |
[Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].
Topics: Aged; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Drug Therapy, Combination; Enalapril; Female; Fumarates; Humans; Hypertension; Indapamide; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2011 |
Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.
Topics: Acute Kidney Injury; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Fumarates; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Renin; Tetrazoles; Valine; Valsartan | 2012 |
Adenylyl cyclase VI mediates vasopressin-stimulated ENaC activity.
Topics: Adenylyl Cyclases; Aldosterone; Animals; Antidiuretic Agents; Antihypertensive Agents; Aquaporin 2; Arginine Vasopressin; Blood Pressure; Epithelial Sodium Channels; Female; Heart Rate; Kidney Tubules, Collecting; Male; Mice; Mice, Knockout; Patch-Clamp Techniques; Renin; Sodium; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2013 |
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cell Size; Drug Interactions; Fibrosis; Fumarates; Mice; Myocardium; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Renin; Signal Transduction; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2013 |
Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial.
Topics: Acute Coronary Syndrome; Aldosterone; Amides; Angiotensin-Converting Enzyme Inhibitors; Down-Regulation; Female; Fumarates; Humans; Male; Middle Aged; Renin-Angiotensin System; Retrospective Studies; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2013 |
Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Hyperaldosteronism; Myocardial Infarction; Rats; Tetrazoles; Valine; Valsartan | 2014 |
Suppression of adrenal βarrestin1-dependent aldosterone production by ARBs: head-to-head comparison.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arrestins; Benzimidazoles; beta-Arrestins; Biphenyl Compounds; CHO Cells; Cricetinae; Cricetulus; GTP-Binding Proteins; Humans; Phosphoproteins; Rats; Receptor, Angiotensin, Type 1; Tetrazoles; Up-Regulation; Valine; Valsartan; Zona Glomerulosa | 2015 |
On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Dihydropyridines; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; Renin-Angiotensin System; Valsartan | 2016 |
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Diuretics; Fibroblasts; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Hydrochlorothiazide; Male; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Recovery of Function; Signal Transduction; Smad2 Protein; Stroke Volume; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
Topics: Aldosterone; Aminobutyrates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cross-Over Studies; Cyclic GMP; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptides; Renin-Angiotensin System; Sodium, Dietary; Tetrazoles; Valsartan | 2019 |
No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril.
Topics: Aldosterone; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Heart Failure; Humans; Renin-Angiotensin System; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left; Veterans | 2021 |
Targeting and Modulation of the Natriuretic Peptide System in Covid-19: A Single or Double-Edged Effect?
Topics: Aldosterone; Aminobutyrates; Anti-Inflammatory Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Cathepsin G; COVID-19 Drug Treatment; Cytokines; Gastrin-Releasing Peptide; Heart Failure; Humans; Natriuretic Peptide, Brain; Natriuretic Peptides; Neprilysin; Renin; Respiratory Distress Syndrome; Tetrazoles; Valsartan | 2022 |
Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care.
Topics: Aldosterone; Ambulatory Care; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Guanylate Cyclase; Heart Failure; Hospitalization; Humans; Ivabradine; Natriuretic Peptides; Potassium; Renin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan | 2022 |
Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
Topics: Aldosterone; Animals; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosis; Kidney; Male; Mice; Natriuretic Peptides; Renal Plasma Flow; Valsartan | 2023 |